Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.

Nigel A Spry¹, Daniel A Galvão, Robert Davies, Shane La Bianca, David Joseph, Andrew Davidson, Richard Prince

¹Faculty of Medicine, University of Western Australia, Crawley, WA, Australia. Nigel.Spry@health.wa.gov.au

Abstract

OBJECTIVE: To investigate changes in bone mineral density (BMD) and osteoporosis, over 3 years of intermittent androgen-suppression therapy (IAST). PATIENTS AND METHODS: This was a Phase II individual cohort study of 72 patients with prostate cancer without metastatic bone disease, enrolled between 1999 and 2002. Patients had 9 months flutamide (250 mg, three times daily) and leuprolide (22.5 mg,…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.